Work

In Vivo Pharmacokinetic Evaluation and In Vitro-In Vivo Correlation of a Sulphated Locust Bean Gum and Cationic Guar Gum Polyelectrolyte Complex Based Controlled Release Tablet of Losartan Potassium in Rabbits

Year: 2026
Type: article
Abstract: Background: Losartan potassium (LP), a widely prescribed angiotensin II receptor blocker, is characterized by low oral bioavailability (~33%) and a short elimination half life (1.5-2.5 h), which together necessitate frequent daily dosing. A controlled-release (CR) tablet formulation of LP (LPC), based on a polyelectrolyte complex (PEC) of sulphated locust bean gum (SLBG) and cationic guar gum (CGG), was previously optimised by Box-Behnken design and shown to sustain in vitro drug release for 12 h. The present study evaluated the in vivo performance of a rabbit equivalent dose PEC tablet (RLPC) and established an in vitro–in vivo correlation (IVIVC). Methods: The rabbit equivalent dose was estimated by the body surface area conversion method, and RLPC tablets were prepared by proportionate downscaling of the optimised LPC formula. A single dose, parallel group pharmacokinetic study was conducted in healthy male rabbits (n = 6/group) that received either a pure LP dispersion (reference) or RLPC tablets (test) by oral gavage. Serial blood samples were withdrawn from the marginal ear vein over 24 h, and plasma LP was quantified by a validated HPLC-PDA method. Non-compartmental pharmacokinetic parameters were derived, group differences were tested by an unpaired Student’s t-test, and a Level A IVIVC was constructed between in vitro fraction dissolved and in vivo fraction absorbed. Results: RLPC produced a lower peak plasma concentration (Cmax 304.33 vs 356.42 ng/mL) with a markedly delayed time to peak (Tmax 6 vs 1 h) relative to the pure drug. Systemic exposure was significantly greater for RLPC, with AUC0–∞ rising from 1113.81 to 4201.65 ng·h/mL (~3.8-fold) and mean residence time increasing from 3.41 to 9.52 h (p < 0.05). Elimination rate constant and half life were not significantly different between treatments (p > 0.05), indicating that the intrinsic elimination of LP was unaffected by the PEC matrix. A strong Level A IVIVC was obtained (R² = 0.9919). Conclusion: The PEC formed between SLBG and CGG effectively sustained the in vivo release of losartan potassium, producing a controlled release pharmacokinetic profile with a good in vitro–in vivo relationship, supporting its potential as a release retarding matrix for oral controlled release drug delivery.
Institution: Andhra University
Language: English
Open Access status: bronze
OpenAlex ID: W7233871606
FWCI:
Cites: 10
Cited by:
Related to: 10